Marshall Wace North America’s Denali Therapeutics DNLI Stock Holding History

Marshall Wace North America’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$11.7M	Buy	231,977 +219,062	+1,696%	+$12.3M	0.05%	321
2021 Q2	$1.01M	Sell	12,915 -263,011	-95%	-$16.3M	﹤0.01%	1005
2021 Q1	$15.8M	Buy	275,926 +225,720	+450%	+$15.1M	0.07%	304
2020 Q4	$4.21M	Sell	50,206 -396,600	-89%	-$24M	0.02%	578
2020 Q3	$16M	Sell	446,806 -394,075	-47%	-$11.9M	0.1%	213
2020 Q2	$20.3M	Sell	840,881 -323,471	-28%	-$7.61M	0.13%	172
2020 Q1	$20.4M	Buy	1,164,352 +766,441	+193%	+$16M	0.15%	154
2019 Q4	$6.93M	Buy	+397,911	New	+$6.62M	0.03%	342
2018 Q1	–	Sell	-45,333	Closed	-$709K	–	1490
2017 Q4	$709K	Buy	+45,333	New	+$815K	﹤0.01%	1065

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Marshall Wace North America's DNLI Position: Q3 2021 in Review

Marshall Wace North America increased its Denali Therapeutics (DNLI) stake by 1,696% in Q3 2021, buying an estimated $12.3M and bringing the position to 231,977 shares worth $11.7M. The position accounts for 0.05% of the portfolio, ranked #321.

Marshall Wace North America first reported a position in DNLI in Q4 2017 and has held it in 9 quarters since. The position peaked at $20.4M in Q1 2020. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

Marshall Wace North America held 231,977 shares of Denali Therapeutics worth $11.7M as of Q3 2021.
Marshall Wace North America bought 219,062 Denali Therapeutics shares in Q3 2021, an estimated $12.3M.
Denali Therapeutics made up 0.05% of Marshall Wace North America's portfolio in Q3 2021, its #321 holding.
Marshall Wace North America first reported a position in Denali Therapeutics in Q4 2017 and has held it in 9 quarters since.
Marshall Wace North America's Denali Therapeutics position peaked at $20.4M in Q1 2020.
214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.